Drug intelligence / Profile preview

TAI-meso-CART

Development stage: Phase 1
Lead developer: Shanghai Genechem Co.
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

TAI-meso-CART is an investigational chimeric antigen receptor T (CAR-T) cell therapy targeting mesothelin, a tumor differentiation antigen overexpressed in several solid tumors. Developed by Shanghai Genechem, this therapy is designed to treat advanced pancreatic carcinoma and potentially other mesothelin-positive cancers. The mechanism of action involves genetically engineered autologous T cells expressing a CAR that recognizes and binds to mesothelin on tumor cells, leading to immunologic cytotoxicity and replacement of dysfunctional or absent T lymphocytes. This approach aims to harness the patient’s immune system for targeted destruction of cancer cells[1][3][4].

Other names: anti-mesothelin chimeric antigen receptor T cell therapy

Targets

Mesothelin

Beyond the preview

Go deeper on TAI-meso-CART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAI-meso-CART.

Explore the full profile